Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7839947 | 0.88 | KDM4E (0.40) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL4128980 | 0.81 | PTGS2 (0.56) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL4120907 | 0.80 | PTGS2 (0.55) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL27501958 | 0.80 | HSD17B10 (0.49) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Nitric Acid SCHEMBL4138682 | 0.79 | PTGS2 (0.54) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL7130432 | 0.79 | PTGS2 (0.59) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL4328045 | 0.78 | HSD17B10 (0.65) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL4134522 | 0.76 | PTGS2 (0.73) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL3814657 | 0.74 | HSD17B10 (0.73) | HSD17B10KDM4ELMNACYP1A2CYP2C9 | |
| SCHEMBL2780096 | 0.74 | HSD17B10 (0.63) | HSD17B10KDM4ELMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| EP-1154999-B1 | NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY | NICOX SA (FR) | 2009-04-15 | — | — | EP | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | disclosed |
| US-6613784-B1 | Cyclooxygenase inhibitors such as 2-acetyloxybenzoic acid 6-(nitroxymethyl)-2-methylpyridinyl ester hydrochloride, having good kinetics, solubility and efficiency; nontoxic | NICOX S.A. (FR) | 2003-09-02 | — | — | US | disclosed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | HSD17B10 550/4885KDM4E 3984/4885LMNA 1771/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | HSD17B10 510/4885KDM4E 2184/4885LMNA 3259/4885 |
| US-20040023890-A1 | Drugs for diabetes | SLC5A2, ADORA2B, UGT2B7 | HSD17B10 647/4885KDM4E 3253/4885LMNA 3188/4885 |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | TPMT, NOX1, CBR1 | HSD17B10 606/4885KDM4E 4320/4885LMNA 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.